Relapsed/Refractory Multiple Myeloma: Subsequent Therapy and Beyond

Download these expert-selected slides on current best practices for later-stage relapsed/refractory multiple myeloma and investigational agents in this setting.
Paul G. Richardson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.71 MB
Released: September 22, 2022

Acknowledgements

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.

Related Content

Comentários de especialistas sobre dados da Reunião Anual da SOHO 2022 sobre os inibidores de BTK para LLC e LCM, do Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commentaires d’experts sur les données de la réunion annuelle de la SOHO 2022 au sujet des inhibiteurs BTK pour le traitement de la LLC et du LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commenti di esperti sui dati della Conferenza annuale della SOHO 2022 sugli inibitori di BTK per il trattamento di CLL e MCL, a cura di Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentario experto de los datos de la Junta Anual de SOHO 2022 sobre inhibidores de la TQB para LLC y LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings